ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behcet’s syndrome"

  • Abstract Number: 1150 • 2017 ACR/ARHP Annual Meeting

    Ocular Involvement Is Exclusive with Genital Ulcer and Skin Lesion in the Early Phase of Behçet’s Disease: Nationwide Japanese Registration.

    Nobuyuki Horita1, Akiko Suwa2, Mitsuhiro Takeno3, Takehito Ishido2, Yohei Kirino4 and Nobuhisa Mizuki5, 1National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 4Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5Yokohama City University, Yokohama, Japan

    Background/Purpose: Behçetfs disease (BD) is a chronic inflammatory syndrome with features of multi-organ involvement and presents with mucocutaneous and ocular symptoms. We have previously found…
  • Abstract Number: 1151 • 2017 ACR/ARHP Annual Meeting

    Clinical Manifestations of BehçEt’s Disease Depending on Sex and Age: Nationwide Japanese Registration

    Takehito Ishido1, Nobuyuki Horita2, Mitsuhiro Takeno3, Mizuho Ishido1, Yohei Kirino4 and Nobuhisa Mizuki5, 1Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 4Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5Yokohama City University, Yokohama, Japan

    Background/Purpose: Behçetfs disease (BD) has a broad spectrum of clinical phenotypes. Sex differences in BD presentation has been one of the major topics of BD…
  • Abstract Number: 1170 • 2017 ACR/ARHP Annual Meeting

    High Output Flow Cytometry Array Classifies Subjects with Uveitis Due to Behcet’s Disease and Sarcoidosis

    Johannes Nowatzky1, Ezra Resnick2, Julia Manasson3, Cristy Stagnar1 and Olivier Manches4, 1Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 2Google Inc., New York, NY, 3Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 4EFS Rhône-Alpes-Auvergne "Immunobiology and Immunotherapy in Chronic Diseases", INSERM - French National Institute of Health and Medical Research, Grenoble, France

    Background/Purpose: The information content of multi-parametric flow cytometry-based immune-phenotyping experiments is routinely underexploited given the paucity of adequate tools and strategies for large-scale unbiased data…
  • Abstract Number: 2102 • 2017 ACR/ARHP Annual Meeting

    The Difference between International Criteria for BD (ICBD) and the BD Criteria of International Study Group (ISG) in Our Behcet’s Disease (BD) Patients Who Fulfilled Japanese BD Criteria

    Tsuyoshi Kobashigawa, Yuki Nanke, Hisashi Yamanaka and Shigeru Kotake, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: In Japan, we have a criteria for BD since 1988. (International Journal of Tissue Reactions. 1988: 10; 59-65.) In Japanese patients diagnosed according to…
  • Abstract Number: 2721 • 2017 ACR/ARHP Annual Meeting

    Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Lucia C. Domínguez-Casas1, Nuria Vegas-Revenga1, Vanesa Calvo-Río1, Natalia Palmou Fontana2, Ricardo Blanco3, Javier Loricera1, MC Gonzalez-Vela4, Emma Beltrán5, Lucía Martínez Costa6, Elia Valls Pascual6, Marisa Hernández Garfella5, Antonio Atanes7, Miguel Cordero Coma8, Joan Miquel Nolla Solé9, Carmen Carrasco Cubero10, Enar Pons11 and Miguel Angel González-Gay2, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 5Hospital General Universitario de Valencia, Valencia, Spain, 6Hospital Peset, Valencia, Spain, 7Hospital Universitario de A Coruña, A Coruña, Spain, 8Hospital de León, León, Spain, 9Hospital Universitari de Bellvitge, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 11Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain

    Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to extraocular manifestations due to Behçet’s disease (BD). Methods: Multicenter study of patients…
  • Abstract Number: 2722 • 2017 ACR/ARHP Annual Meeting

    Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Lucia C. Domínguez-Casas1, Nuria Vegas-Revenga1, Vanesa Calvo-Río1, Emma Beltrán2, Juan Sánchez-Burson3, Marina Mesquida4, Alfredo Adán4, M Victoria Hernández4, Javier López-Longo5, Marisa Hernández Garfella2, Elia Valls Pascual6, Lucía Martínez Costa6, Agustí Sellas-Fernandez7, José L. García-Serrano8, José-Luis Callejas-Rubio8, Norberto Ortego8, José M. Herreras9, Alejandro Fonollosa10, Olga Maíz11, Ana Blanco12, Ignacio Torre13, C. Fernandez-Espartero14, V. Jovani15, D. Peiteado Lopez16, David Díaz Valle17, Esperanza Pato17, J. Cruz18, C. Fernandez-Cid18, Elena Aurrecoechea19, M. García20, Miguel A. Caracuel21, Antonio Atanes22, F. Francisco23, Santos Insúa24, S. Gonzalez-Suárez25, A. Sánchez-Andrade26, L. Linares27, F. Romero-Bueno28, A. J. García29, R. Almodovar30, Enrique Mínguez31, Carmen Carrasco Cubero32, E. Raya Álvarez8, M. Alcalde-Villar33, C. Fernández-Carbadillo34, FA. Pagés35, MC Gonzalez-Vela36, Rosalia Demetrio37, Enar Pons37, Jose L. Hernández38, Miguel Angel González-Gay39 and Ricardo Blanco40, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital General Universitario de Valencia, Valencia, Spain, 3Hospital de Valme, Sevilla, Spain, 4Hospital Clinic, Barcelona, Spain, 5Hospital Gregorio Marañón, Madrid, Spain, 6Hospital Peset, Valencia, Spain, 7Hospital Vall d´Hebron, Barcelona, Spain, 8Hospital San Cecilio, Granada, Spain, 9Hospital Universitario IOBA, Valladolid, Spain, 10Hospital de Cruces, Bilbao, Spain, 11Hospital Donosti, San Sebastian, Spain, 12Ophthalmology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 13Hospital Basurto, Bilbao, Spain, 14Hospital Universitario de Móstoles, Madrid, Spain, 15Hospital General Alicante, Alicante, Spain, 16Hospital Universitario La Paz, Madrid, Spain, 17Hospital Clínico San Carlos, Madrid, Spain, 18Hospital Pontevedra, Pontevedra, Spain, 19Hospital Sierrallana, Torrelavega, Spain, 20Hospital La Princesa, Madrid, Spain, 21Hospital Córdoba, Córdoba, Spain, 22Hospital Universitario de A Coruña, A Coruña, Spain, 23Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, 24Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, 25Hospital Cabueñes, Gijón, Spain, 26Hospital Lucus Augusti, Lugo, Spain, 27Hospital Arrixaca, Murcia, Spain, 28Fundación Jiménez Díaz, Madrid, Spain, 29Hospital 12 de Octubre, Madrid, Spain, 30Hospital Universitario Fundación Alcorcón, Madrid, Spain, 31Hospital Clínico Zaragoza, Zaragoza, Spain, 32Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 33Hospital Severo Ochoa, Madrid, Spain, 34Hospital General Universitario de Elda, Alicante, Spain, 35Complejo Asistencial de Palencia, Palencia, Spain, 36Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 37Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, 38Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 39Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Johannesburg, South Africa, 40Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Uveitis is a severe manifestation of Behçet Disease (BD). The treatment is based on corticosteroids and conventional immunosuppressive drugs. In refractory cases, anti-TNFα had…
  • Abstract Number: 2723 • 2017 ACR/ARHP Annual Meeting

    Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Nuria Vegas-Revenga1, Lucia C. Domínguez-Casas1, Vanesa Calvo-Río1, Emma Beltrán2, Juan Sánchez-Burson3, Marina Mesquida4, Alfredo Adán4, M Victoria Hernández4, Marisa Hernández Garfella2, Elia Valls Pascual5, Lucía Martínez Costa5, Agustí Sellas-Fernandez6, Miguel Cordero Coma7, Manuel Díaz-Llopis8, Roberto Gallego8, David Salom8, Norberto Ortego9, José L. García-Serrano9, José-Luis Callejas-Rubio9, José M. Herreras10, Ángel M García-Aparicio11, Olga Maíz12, Ana Blanco13, Ignacio Torre14, David Díaz Valle15, Esperanza Pato15, Elena Aurrecoechea16, Miguel A. Caracuel17, Fernando Gamero18, Enrique Mínguez19, Carmen Carrasco Cubero20, Alejandro Olive21, Julio Vázquez22, Oscar Ruiz Moreno23, Fernando Jiménez-Zorzo24, Javier Manero24, Myriam Gandia Martinez25, Esteban Rubio-Romero26, F. Javier Toyos-Sáenz de Miera27, Javier López-Longo28, JM Nolla29, Marcelino Revenga30, Rosalia Demetrio31, Enar Pons31, Miguel Angel González-Gay1 and Ricardo Blanco32, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital General Universitario de Valencia, Valencia, Spain, 3Hospital de Valme, Sevilla, Spain, 4Hospital Clinic, Barcelona, Spain, 5Hospital Peset, Valencia, Spain, 6Hospital Vall d´Hebron, Barcelona, Spain, 7Hospital de León, León, Spain, 8Hospital Universitario La Fe, Valencia, Spain, 9Hospital San Cecilio, Granada, Spain, 10Hospital Universitario IOBA, Valladolid, Spain, 11Hospital Donosti, San Sebastián, Spain, 12Hospital Donosti, San Sebastian, Spain, 13Ophthalmology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 14Hospital Basurto, Bilbao, Spain, 15Hospital Clínico San Carlos, Madrid, Spain, 16Hospital Sierrallana, Torrelavega, Spain, 17Hospital Córdoba, Córdoba, Spain, 18Hospital San Pedro Alcántara, Cácerer, Spain, 19Hospital Clínico Zaragoza, Zaragoza, Spain, 20Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 21Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 22Hospital de Ferrol, A Coruña, Spain, 23Ophthalmology and Rheumatology., Ophtalmology. Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 24Hospital Miguel Servet, Zaragoza, Spain, 25Hospital Puerta del Mar, Cádiz, Spain, 26Hospital Universitario Virgen del Rocío, Sevilla, Spain, 27Hospital Universitario Virgen Macarena, Sevilla, Spain, 28Hospital Gregorio Marañón, Madrid, Spain, 29Hospital Universitari de Bellvitge, Barcelona, Spain, 30Hospital Universitario Ramón y Cajal, Madrid, Spain, 31Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, 32Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Adalimumab (ADA) therapy has been approved by the EMA and the FDA in non-infectious and non-anterior uveitis. After loading, the maintenance dose is 40…
  • Abstract Number: 2724 • 2017 ACR/ARHP Annual Meeting

    Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Javier Loricera1, Nuria Vegas-Revenga1, Lucia C. Domínguez-Casas1, Jose L. Hernández2, Clara Moriano3, Maria Dolores García-Armario4, Iván Castelvi5, Francisca Sivera6, Jaime Calvo-Alen7, Isabel de la Morena8, Francisco Ortiz-Sanjuán9, José Andrés Román-Ivorra9, Ana Pérez-Gómez10, MC Gonzalez-Vela11, Miguel Angel González-Gay1 and Ricardo Blanco12, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Complejo Asistencial Universitario de León, León, Spain, 4Hospital de Xàtiva, Xàtiva, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6Hospital General Universitario de Elda, Elda, Spain, 7Hospital Universitario Araba, Vitoria, Spain, 8Hospital General Universitario de Valencia, Valencia, Spain, 9Hospital La Fe, Valencia, Spain, 10Hospital Príncipe de Asturias, Alcalá de Henares, Spain, 11Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 12Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…
  • Abstract Number: 108 • 2017 Pediatric Rheumatology Symposium

    Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil

    Milagro Raquel Tovar-Avila1, Francisco Hugo Gomes2, Lucenir Da Silva3, Virginia Ferriani4 and Luciana Carvalho2, 1Pediatric Reumatology Division, Ribeirão Preto Medical School - University of São Paulo, Rbeirão Preto, Brazil, 2Pediatric Rheumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil, 3Rheumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil, 4Pediatric Reumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil

    Background/Purpose: Behet's disease (BD) is a rare systemic inflammatory disease with nonspecific clinical presentation that can mimic infections, tumors and other diseases. Diagnostic delay of…
  • Abstract Number: 109 • 2017 Pediatric Rheumatology Symposium

    Clinical features of pediatric Behçet’s disease patients in Japan

    Ken-ichi Yamaguchi1 and Satoshi Fujikawa2, 1Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 2Immuno-Rheumatology Center, St.luke's International Hospital, Tokyo, Japan

    Background/Purpose: To diagnose pediatric patients as Behçet’s disease (BD) is challenging. Sensitivity of four BD criteria, three BD criteria made for adult patients and Paediatric…
  • Abstract Number: 182 • 2016 ACR/ARHP Annual Meeting

    Histone Methylation in γδ T Cells As a Biomarker of Behcet’s Disease Activity

    Yoshimi Aizaki1,2, Yasuto Araki1,2, Kojiro Sato1, Kazuhiro Yokota1 and Toshihide Mimura1,2, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Behcet’s disease (BD) is a chronic recurrent, multisystem inflammatory disorder. The phenotypic characteristics include oral aphtha, genital ulcers, uveitis and skin lesions. No specific…
  • Abstract Number: 2967 • 2016 ACR/ARHP Annual Meeting

    Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise

    Alexa Meara1, Yesim Ozguler2, Alfred Mahr3, Haner Direskeneli4, Ahmet Gul5, Yusuf Yazici6, Hasan Yazici2, Peter A. Merkel7 and Gulen Hatemi2, 1Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Hospital Saint-Louis, Paris, France, 4Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 5Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 6Rheumatology, New York University Medical Center, La Jolla, CA, 7Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: An unmet need for reliable, validated, and widely accepted outcome measures for trials in BehetÕs syndrome (BS) was identified through: i) a systematic review;…
  • Abstract Number: 879 • 2016 ACR/ARHP Annual Meeting

    Associated Inflammatory Diseases in Takayasu’s Arteritis: The Many Faces of a Disease

    Sinem Nihal Esatoglu1, Ayse Merve Celik2, Didar Ucar3, Aykut Ferhat Celik4, Serdal Ugurlu5, Gulen Hatemi5, Melike Melikoglu5, Izzet Fresko5, Vedat Hamuryudan5, Huri Ozdogan6, Sebahattin Yurdakul5, Hasan Yazici5 and Emire Seyahi5, 1Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, 5Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 6Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

    Background/Purpose: Case reports and series suggest that Takayasu’s arteritis (TA) can co-exist with various inflammatory disorders. Inflammatory bowel disease [(IBD; Crohn's disease (CD) or ulcerative…
  • Abstract Number: 2978 • 2016 ACR/ARHP Annual Meeting

    Psychiatric Involvement and Behcet’S Syndrome: Does Bipolar Disorder Represent a Clinical Feature of the Disease?

    Rosaria Talarico1, Elena Elefante2, Laura Palagini3, Anna d'Ascanio4, Chiara Stagnaro4, Chiara Tani4, Chiara Baldini4, Rossella Neri1 and Marta Mosca4, 1Rheumatology Unit, University of Pisa, PISA, Italy, 2RHEUMATOLOGY UNIT, University of Pisa, Pisa, Italy, 3Psychiatric Unit, University, PISA, Italy, 4Rheumatology Unit, University of Pisa, Pisa, Italy

    Background/Purpose: Frequency of psychiatric disorders in Behçet’s syndrome (BS) is a debated issue: while some experts attribute their presence to the chronicity of the illness,…
  • Abstract Number: 1202 • 2016 ACR/ARHP Annual Meeting

    Characteristic Compositional and Functional Alteration of Gut Microbiota in Patients with Behcet’s Disease

    Noboru Suzuki1, Jun Shimizu2 and Takao Kubota3, 1Department of Immunology and medicine, St. Marianna University School of Medicine, Kawasaki-shi, 216-8511, Japan, 2Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 3The Japan Self Defense Forces Central Hospital, Tokyo, Japan

    Background/Purpose:  We have presented evidence that the frequency of helper T (Th)17 cells increased and the cells had already been activated in vivo in patients…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology